Genetron Holdings (Genetron Holdings) ROCE % : -64.85% (As of Jun. 2022)

View and export this data going back to 2020. Start your Free Trial

What is Genetron Holdings ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Genetron Holdings's annualized ROCE % for the quarter that ended in Jun. 2022 was -64.85%.

Genetron Holdings ROCE % Historical Data

The historical data trend for Genetron Holdings's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genetron Holdings ROCE % Chart

Genetron Holdings Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

ROCE %

Get a 7-Day Free Trial

-71.49

-215.54

-294.95

-33.74

-71.47

Genetron Holdings Quarterly Data
	Dec17	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22
ROCE %	Get a 7-Day Free Trial													-33.37	-49.54	-59.82	-64.85	-

Genetron Holdings ROCE % Calculation

Genetron Holdings's annualized ROCE % for the fiscal year that ended in Dec. 2022 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2022 )		(A: Dec. 2021 )		(A: Dec. 2022 )
	=	-100.283	/	( ( (238.271 - 41.62)	+	(139.898 - 55.921) )	/ 2 )
	=	-100.283	/	( (196.651	+	83.977)	/ 2 )
	=	-100.283	/	140.314
	=	-71.47 %

Genetron Holdings's ROCE % of for the quarter that ended in Jun. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2022 )		(Q: Mar. 2022 )		(Q: Jun. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2022 )		(Q: Mar. 2022 )		(Q: Jun. 2022 )
	=	-101.312	/	( ( (209.412 - 39.327)	+	(194.672 - 52.291) )	/ 2 )
	=	-101.312	/	( ( 170.085	+	142.381 )	/ 2 )
	=	-101.312	/	156.233
	=	-64.85 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2022) EBIT data.

Genetron Holdings (NAS:GTH) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Genetron Holdings ROCE % Related Terms

Thank you for viewing the detailed overview of Genetron Holdings's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Genetron Holdings (Genetron Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genetron Holdings Ltd (NAS:GTH) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 8 Life Science Parkway, 1-2nd Floor, Building 11, Zone 1, Changping District, Beijing, CHN, 102206

Website

https://www.genetronhealth.com

Genetron Holdings Ltd is an oncology company in China. It is specialized in cancer molecular profiling and harnesses advanced technologies in molecular biology and data science to transform cancer treatment. The company's operating segment includes Diagnosis and monitoring - provision for LDT services; Diagnosis and monitoring - sale of IVD products and Development services. It generates maximum revenue from the Diagnosis and monitoring - provision for LDT services segment.